The Association of British Pharmaceutical Industry (ABPI) welcomes the strong focus on science and innovation in the Government's green paper on Industrial Strategy, set out today by the Prime Minister. This is further demonstration of their support for research and development which is a cornerstone of the UK's strength in life sciences.
The paper also refers to the implementation of recommendations made in the Accelerated Access Review and touches on how the NHS can facilitate faster access to innovative medicines, both of which will benefit patients and is supported by the ABPI.
Commenting on the Industrial Strategy announcement, ABPI's Chief Executive, Mike Thompson, said: "We are pleased to see that the Government has once again prioritised science and innovation.
A successful Industrial Strategy will help deliver a strong pharmaceutical industry for the UK economy and improve healthcare for patients. Our sector is worth £60bn a year to our economy, employing more than 220,000 highly skilled people across the UK. If we play to our strengths, we can go even further and create one of the world's pre-eminent hubs for life sciences research and investment.
The NHS can best respond to the increasing healthcare demands of our population by embracing innovation. By working together to improve how we gather and use health data we can deliver the next generation of medicines to UK patients.
The Life Sciences industry is ready and well-placed to play a leading role in creating a prosperous and dynamic post-Brexit Britain."
The APBI and representatives from leading UK pharmaceutical companies are founding members of the Life Sciences Industrial Strategy Board, chaired by Sir John Bell, which is working to deliver a strategy for life sciences that will strengthen the UK's world-class sector over the next decade.
ABPI Press Office Email: email@example.com Telephone during work hours (9am to 5pm Monday to Friday): +44 (0) 20 7747 7147 or +44 (0) 20 7747 1441 Telephone out of hours (5pm to 9am and weekends): +44 (0) 20 7747 1445
About the ABPI
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.